PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients unde… Read more
Market Cap & Net Worth: PolyPid (PYPD)
PolyPid (NASDAQ:PYPD) has a market capitalization of $83.01 Million ($83.01 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21172 globally and #7619 in its home market, demonstrating a 9.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PolyPid's stock price $4.56 by its total outstanding shares 18204002 (18.20 Million).
PolyPid Market Cap History: 2020 to 2026
PolyPid's market capitalization history from 2020 to 2026. Data shows change from $5.41 Billion to $83.01 Million (-56.97% CAGR).
Index Memberships
PolyPid is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #577 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1904 of 3165 |
Weight: PolyPid's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PolyPid Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PolyPid's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PYPD by Market Capitalization
Companies near PolyPid in the global market cap rankings as of March 19, 2026.
Key companies related to PolyPid by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PolyPid Historical Marketcap From 2020 to 2026
Between 2020 and today, PolyPid's market cap moved from $5.41 Billion to $ 83.01 Million, with a yearly change of -56.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $83.01 Million | +5.07% |
| 2025 | $79.01 Million | +42.76% |
| 2024 | $55.34 Million | -20.00% |
| 2023 | $69.18 Million | -81.84% |
| 2022 | $380.92 Million | -87.85% |
| 2021 | $3.13 Billion | -42.02% |
| 2020 | $5.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PolyPid was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $83.01 Million USD |
| MoneyControl | $83.01 Million USD |
| MarketWatch | $83.01 Million USD |
| marketcap.company | $83.01 Million USD |
| Reuters | $83.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.